Alnylam Pharmaceuticals, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-05-27. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Benjamin F. Cravatt, effective 2026-06-01
Effective as of June 1, 2026, the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Company"), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company's Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.
Find people with the same kind of experience as the senior executive at Alnylam Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Alnylam Pharmaceuticals, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Alnylam Pharmaceuticals, Inc. is in the news or changes leadership.
Get an alert when Alnylam Pharmaceuticals, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Alnylam Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.